AEON Biopharma Sets Annual Shareholder Meeting

About this update from Aeon Biopharma, Inc.

[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7DDSqhC8eFJz3b_vK.hWvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUx/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 -","length":73,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that its Annual Shareholder Meeting will be held at 10:00 am Pacific Time (PT) on Wednesday, June 17, 2026 and will be held in the Company’s offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. Meeting materials are expected to be made available to shareholders on or about April 29, 2026.","length":583,"tagName":"p"},{"type":"text","content":"NYSE Required Disclosure Regarding Audit Opinion","length":48,"tagName":"p"},{"type":"text","content":"As required by Section 610(b) of the NYSE American Company Guide, the Company also hereby provides notice that its audited consolidated financial statements for the fiscal year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K, contained an audit report from its independent registered public accounting firm that included a going concern qualification, which is not uncommon for development-stage biopharmaceutical companies with ongoing capital requirements. This disclosure does not reflect any change to the Company’s previously filed financial statements or the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The going concern qualification reflects the Company’s liquidity position as of the audit date. The Company expects its cash and cash equivalents to fund operations into the third quarter of 2026.","length":866,"tagName":"p"},{"type":"text","content":"About AEON Biopharma","length":20,"tagName":"p"},{"type":"text",...

More updates from Aeon Biopharma, Inc.